comparemela.com

Latest Breaking News On - European commissionas - Page 1 : comparemela.com

Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO? and its combination with ezetimibe, NUSTENDI?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk

NILEMDO? (bempedoic acid), a first-in-class, oral treatment and NUSTENDI? (bempedoic acid ezetimibe fixed-dose combination) receive label update approval from the European Commission as treatments

United kingdomDaiichi sankyo europe gmbSheldon koenigAlberico catapanoGillian dsouzaDaiichi sankyoOliver appelhansDaiichi sankyo europeUniversity of milanEuropean atherosclerosis societyEuropean society of cardiologyEuropean medicines agencyEuropean commissionHead of europe specialty divisionEsperion therapeutics incEuropean commissionas

Sanofi: Libtayo (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma

Libtayo (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma Approval based on data

United statesFrance generalEva schaefer jansenKaplan meierSuzanne grecoArnaud delepineFelix lauscherVesna tosicFara berkowitzPeterc adamsonAshleigh kossNatalie phamTaylor ramseyRegeneron pharmaceuticals incRegeneron genetics centerEuropean commission

vimarsana © 2020. All Rights Reserved.